FDA approvals
Insmed’s FDA approval of BRINSUPRI™ (brensocatib) for non-cystic fibrosis bronchiectasis marks a new era for neutrophil-targeted therapies. Originally discovered by AstraZeneca, brensocatib's success could reshape China’s respiratory drug innovation and investment landscape.
National Reimbursement Drug List
On August 12, 2025, NHSA published the initial review results for China’s 2025 NRDL and Commercial Innovative Drug List, marking the first step toward expanded reimbursement access for innovative therapies.
China Pharma
China’s pharma industry transformed (2015–2024) into a global hub with 4,382 drug candidates, $9.26B in BsAb deals, and 2025 FDA approvals like Sunvozertinib, Taletrectinib, and Penpulimab. With $130.4B in PD-1/VEGF and other deals, plus CGT advances, it’s reshaping pharma.
DPP-1 inhibitor
On August 11, Fosun Pharma took another step in its strategy to globalize its innovation pipeline, out-licensing its oral small-molecule DPP-1 inhibitor XH-S004 to San Francisco-based Expedition Therapeutics for territories outside mainland China, Hong Kong, and Macau. The deal could be worth up to $645 million in upfront, milestone, and
dulaglutide biosimilar
China’s NMPA approved Boyouping® (BA5101), the world’s first dulaglutide biosimilar and first domestic product for type 2 diabetes. Developed by Boan Biotech and commercialized by Shanghai Pharma, Boyouping® matches Eli Lilly’s Trulicity® in efficacy and safety, with plans for global expansion.
FDA approvals
As of August 12, 2025, the FDA has approved 25 novel drugs, emphasizing precision medicine, rare disease advances, and a notable increase in China-origin therapies gaining U.S. approval. This analysis covers key drugs, modalities, and the evolving China biotech footprint.
Bispecific Antibodies
China’s BsAb deals hit $9.26B in H1 2025. Innovent, Hengrui, and SystImmune shift beyond PD-(L)1/VEGF to Ang2/VEGF, T-cell engagers, and novel dual-pathway drugs.
Nuclear Medicine
China's nuclear medicine industry is growing fast due to innovation, policy support, and rising demand. This report compares key players—Yantai Dongcheng, CIRC, Grand Pharmaceutical, Shanghai Pharma—to global benchmarks like Novartis’ Pluvicto and Lutathera.
cell and gene therapy
China’s cell and gene therapy (CGT) ecosystem is rapidly evolving with fast-track IND/NDA pathways, expanding pipelines, and global relevance. This analysis breaks down the key takeaways from a major Nature Reviews article and explores what they mean for developers, investors, and regulators.
China Biotech
Outbound licensing surges as China’s biotech sector hits its stride. Key deals, IPOs, IND reform, GLP-1 momentum, and TCE/autoimmune advances.
XtalPi
XtalPi teams up with DoveTree in a $6 billion AI-powered drug discovery partnership to develop new small molecules and antibodies across major disease areas.
Biotech Deals
Madrigal Pharmaceuticals has partnered with China’s CSPC in a $2B deal for SYH2086, an oral GLP-1 candidate for MASH and metabolic disease.